Fatigue

Rumpled empty bed in dim early-morning light
Pathological fatigue is out of proportion to recent activity, persists despite adequate rest, and impairs work, social life or daily activities
Infographic: sleepiness, weakness and breathlessness as fatigue look-alikes
Fatigue is distinguished from sleepiness, muscle weakness and breathlessness, because each points to a different set of causes and tests
Blood smear: normal red cells beside small pale iron-deficient cells
Anemia, most often from iron deficiency, is one of the most common causes of fatigue in primary care

Table of Contents

  1. Overview
  2. Evaluating Fatigue — Red Flags vs Common Causes
  3. Medical Causes — Endocrine
  4. Medical Causes — Cardiac and Pulmonary
  5. Medical Causes — Infectious and Hematologic
  6. Medical Causes — Rheumatologic and Other
  7. Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS)
  8. Diagnostic Workup
  9. Treatment by Cause
  10. Connections
  11. Key Research Papers
  12. Featured Videos

Overview

Fatigue is one of the most common presenting complaints in primary care, accounting for 20–30% of general practitioner visits across all age groups. It is a subjective feeling of tiredness, lack of energy, or exhaustion that is not relieved by ordinary rest. Clinically, it is important to distinguish fatigue from three overlapping symptoms: sleepiness (a compelling desire to fall asleep, primarily driven by sleep debt or circadian disruption), weakness (a measurable reduction in muscle force generation, as in myopathy or neuromuscular disease), and dyspnea (effort limitation due to breathlessness, as in heart failure or chronic obstructive pulmonary disease (COPD)). Patients often conflate these, and doctors separate them with a careful history, because each implies a different differential diagnosis and workup.

Normal fatigue is physiologically expected after strenuous exertion, sleep deprivation, or acute illness — it resolves with adequate rest, is proportionate to the precipitating cause, and does not impair baseline function once recovery is complete. Pathological fatigue is disproportionate to any recent activity, persists despite adequate rest, and meaningfully impairs occupational performance, social function, or activities of daily living. The onset of pathological fatigue, its relationship to exertion (including delayed worsening 24–48 hours post-activity — post-exertional malaise), associated symptoms, and time course are the most critical history elements.

Fatigue is classified by duration: acute (<1 month), subacute (1–6 months), and chronic (>6 months). The differential diagnosis shifts substantially across these categories. Acute fatigue is usually infectious, medication-related, or stress-driven. Chronic fatigue has a broader differential that includes psychiatric disorders (depression is the single most common cause in primary care, accounting for approximately 40% of unselected chronic fatigue cases), sleep disorders (particularly obstructive sleep apnea), metabolic and endocrine disease, rheumatologic conditions, chronic infections, and — when criteria are met after exclusion of other causes — myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS).

Evaluating Fatigue — Red Flags vs Common Causes

Red Flags Requiring Urgent Evaluation

Most Common Causes in Primary Care

Medical Causes — Endocrine

Hypothyroidism is a cardinal cause of fatigue and is frequently missed because its onset is gradual. The classic constellation includes fatigue, cold intolerance, weight gain, constipation, dry skin, hair thinning, periorbital puffiness, and bradycardia. Even subclinical hypothyroidism — defined as an elevated thyroid-stimulating hormone (4.5–10 mIU/L) with a normal free T4 — is reported to cause fatigue and cognitive slowing in a substantial proportion of patients. In the TRUST trial, however, 737 adults aged 65 and over with subclinical hypothyroidism (TSH 4.60–19.99 mIU/L) took levothyroxine or a dummy pill for a year; tiredness scores did not differ between the groups (difference 0.4 points on a 0–100 scale), and the authors reported that levothyroxine “provided no apparent benefits” in older people with this condition. Diagnosis: thyroid-stimulating hormone as initial screen; add free T4 if thyroid-stimulating hormone is abnormal. Treatment: levothyroxine, with the dose usually adjusted to a goal thyroid-stimulating hormone of 0.5–2.5 mIU/L; energy improvement typically requires 6–8 weeks at target dose. Some patients report superior symptom control with combined T4 + T3 (liothyronine) therapy, though evidence from randomized trials is mixed.

Adrenal insufficiency presents with profound, often disabling fatigue accompanied by hyperpigmentation (primary adrenal insufficiency only — caused by excess adrenocorticotropic hormone (ACTH) stimulating melanocortin receptors in skin), orthostatic hypotension, hyponatremia, and hyperkalemia. Secondary adrenal insufficiency (from pituitary disease or glucocorticoid withdrawal) lacks hyperpigmentation but is otherwise similar. Diagnosis: morning cortisol (8 AM); if borderline (3–18 mcg/dL), it is confirmed with an adrenocorticotropic hormone stimulation test (cosyntropin 250 mcg intravenous, IV). Addisonian crisis risk is substantial during intercurrent illness — standard care gives patients sick-day rules for doubling the glucocorticoid dose and an emergency injectable kit.

Diabetes mellitus causes fatigue through multiple mechanisms: hyperglycemia impairs cellular energy metabolism directly, while hypoglycemic episodes (in treated patients) cause acute profound fatigue. The classic triad of polyuria, polydipsia, and fatigue in a patient with risk factors (obesity, family history, age >45) is a standard reason for prompt glucose and hemoglobin A1c testing. Even well-controlled diabetes can cause fatigue through recurrent hypoglycemia, autonomic neuropathy, or sleep disruption from nocturia.

Hypercalcemia causes the classically described constellation of "bones, groans, moans, and stones" — fatigue, constipation, polyuria, nephrolithiasis, and bone pain. Mild hypercalcemia (10.5–12 mg/dL) commonly presents with fatigue alone. The two most common causes in outpatients are primary hyperparathyroidism and malignancy. Diagnosis: total calcium (corrected for albumin) + intact parathyroid hormone (PTH); parathyroid hormone-independent hypercalcemia (low parathyroid hormone, elevated calcium) points toward malignancy or granulomatous disease.

Male hypogonadism (low testosterone) manifests as fatigue, reduced libido, mood disturbances (depression-like), reduced muscle mass, and increased adiposity. Prevalence rises with age; also common in men with chronic illness, opioid use, or obesity. Diagnosis: morning total testosterone (8–10 AM; repeated if borderline); luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels then distinguish primary (testicular) from secondary (pituitary) hypogonadism.

Cushing's syndrome paradoxically combines fatigue with symptoms of cortisol excess: truncal obesity, easy bruising, purple abdominal striae, proximal muscle weakness, hypertension, hyperglycemia, and osteoporosis. Screening tests include 24-hour urine free cortisol, late-night salivary cortisol (two measurements), and low-dose (1 mg) overnight dexamethasone suppression test. Fatigue in Cushing's is likely mediated by sleep disruption, metabolic derangements, and hypothalamic-pituitary-adrenal (HPA) axis dysregulation.

Medical Causes — Cardiac and Pulmonary

Heart failure is a major cause of exertional fatigue, classically accompanied by dyspnea (especially orthopnea and paroxysmal nocturnal dyspnea), dependent edema, and reduced exercise tolerance. NT-proBNP or BNP is the best initial biomarker; echocardiogram characterizes systolic vs. diastolic dysfunction, ejection fraction, and valvular disease. Treatment follows the HFrEF (reduced ejection fraction) guideline-directed medical therapy framework: loop diuretics for volume overload, angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB)/ARNI (sacubitril-valsartan), beta-blockers (carvedilol, metoprolol succinate), and mineralocorticoid antagonists (spironolactone, eplerenone).

Valvular heart disease — particularly aortic stenosis — produces the classic triad of exertional fatigue, syncope (or pre-syncope), and exertional chest pain. Severe AS is a hemodynamic emergency; mean gradient >40 mmHg on echo with reduced valve area (<1.0 cm²) is the usual threshold for valve intervention. Mitral regurgitation causes volume-overload fatigue with a characteristic holosystolic murmur radiating to the axilla. Echocardiography is diagnostic for all valvular lesions.

Obstructive sleep apnea (OSA) is arguably the most under-recognized cause of chronic fatigue, especially in middle-aged men. Key features: loud snoring, witnessed apneas by bed partner, nocturia, morning headaches, and unrefreshing sleep. The Epworth Sleepiness Scale (ESS score >10) and STOP-BANG questionnaire (≥3 points: high risk) are validated screening tools. Polysomnography (PSG) is the gold standard; home sleep apnea testing is used for high-pretest-probability patients without significant comorbidities. CPAP is first-line treatment; 10% weight loss can eliminate OSA in overweight patients; mandibular advancement devices are effective for mild-to-moderate OSA in patients who cannot tolerate CPAP.

Chronic obstructive pulmonary disease causes fatigue through multiple mechanisms: impaired gas exchange, increased work of breathing, systemic inflammation, and deconditioning. Spirometry showing FEV1/FVC <0.70 post-bronchodilator is diagnostic. Fatigue in chronic obstructive pulmonary disease correlates more strongly with exercise capacity (6-minute walk distance) than with FEV1 alone.

Pulmonary arterial hypertension (PAH) presents insidiously with exertional fatigue, progressive dyspnea, and ultimately syncope. Mean age at diagnosis is 50–65 years; female predominance. Estimated right ventricular systolic pressure >40 mmHg on echo leads to right heart catheterization for confirmation (mPAP ≥20 mmHg). Treatment includes pulmonary vasodilators (phosphodiesterase-5 inhibitors, endothelin receptor antagonists, prostacyclin analogs).

Medical Causes — Infectious and Hematologic

Anemia produces fatigue through reduced oxygen-carrying capacity — pallor, exertional dyspnea, palpitations, and tachycardia accompany the fatigue in moderate-to-severe cases. The specific type determines evaluation and treatment. Iron deficiency anemia (IDA): microcytic MCV <80 fL + ferritin <30 ng/mL; most common in premenopausal women (menstrual loss) and in gastrointestinal blood loss; in men and postmenopausal women, guidelines treat iron deficiency anemia as a reason to look for bleeding in the gut (for example by colonoscopy) rather than assume a dietary cause. Vitamin B12 deficiency: macrocytic MCV >100 fL; subacute combined degeneration of the spinal cord (posterior columns + corticospinal tracts) in severe cases; methylmalonic acid and homocysteine are measured if B12 is borderline (200–400 pg/mL). Anemia of chronic disease (ACD): normocytic, low serum iron, but elevated ferritin and transferrin saturation <20%; occurs in chronic infections, autoimmune disease, and malignancy; treatment targets the underlying condition, with intravenous iron or erythropoiesis-stimulating agents (ESAs) used per disease-specific guidelines.

Infectious mononucleosis (Epstein-Barr virus, EBV) is the classic post-infectious fatigue syndrome in adolescents and young adults (peak age 15–25). The triad of fever, exudative pharyngitis, and cervical lymphadenopathy with splenomegaly is typical. Splenic rupture (rare but life-threatening) is the reason contact sports are usually held off until the spleen returns to normal size (often checked by ultrasound). Diagnosis: monospot (heterophile antibody) — false-negative rate 10–15% in first week; EBV VCA IgM is more sensitive. Post-viral fatigue lasting 4–6 weeks after acute illness is typical and expected; fatigue persisting >6 months may represent transition to myalgic encephalomyelitis/chronic fatigue syndrome in susceptible individuals.

Human immunodeficiency virus: the 2006 U.S. Centers for Disease Control and Prevention (CDC) recommendations call for routine opt-out human immunodeficiency virus screening of all patients aged 13–64 in health-care settings, and doctors also test people with unexplained fatigue regardless of perceived risk. The 4th-generation human immunodeficiency virus Ag/Ab combination test detects both p24 antigen and human immunodeficiency virus antibodies — sensitivity exceeds 99.9% at 4 weeks post-exposure. Acute human immunodeficiency virus (primary infection, 2–4 weeks post-exposure) can present as a mononucleosis-like illness with fever, pharyngitis, lymphadenopathy, rash, and profound fatigue — a presentation often initially misdiagnosed.

Chronic hepatitis C is often asymptomatic for decades, but fatigue is the most commonly reported symptom and may precede detectable liver fibrosis. Risk factors: intravenous drug use (historical or current), blood transfusion before 1992, or tattoos with non-sterile equipment. Since 2020 the CDC recommends hepatitis C screening at least once for every adult aged 18 and over (except in settings where fewer than 1 in 1,000 people carry the virus) and in every pregnancy, replacing its 2012 advice to screen people born 1945–1965; anyone with risk factors is tested whatever their age, and the CDC notes that 8–12 weeks of all-oral medicine cures most people. Diagnosis: anti-HCV antibody → confirmatory HCV RNA if antibody positive. Effective treatment with direct-acting antivirals (DAAs) achieves sustained virologic response (SVR, functional cure) in >95% of treated patients, with significant improvement in fatigue scores post-SVR.

Tuberculosis can present with fatigue as a prominent early symptom before pulmonary symptoms develop, particularly in immunocompromised patients, immigrants from high-burden countries, and incarcerated individuals. The classic triad: night sweats, weight loss, and productive cough ± hemoptysis. Screening: TST (tuberculin skin test) or an interferon-gamma release assay (IGRA) blood test. Active tuberculosis: chest computed tomography (CT) + sputum AFB smear/culture and a nucleic acid amplification test (NAAT), such as a rapid molecular TB test.

Lyme disease in the early disseminated phase can produce fatigue, arthralgias, and neurological symptoms (Lyme neuroborreliosis). Fatigue without a prior erythema migrans rash or tick exposure history is worked up for other causes before it is attributed to Lyme. Diagnosis: two-tier serologic testing (ELISA followed by Western blot); false-positive antinuclear antibody (ANA) and rheumatoid factor can confuse the picture. Post-Lyme disease syndrome — persistent fatigue after adequately treated Lyme — is a recognized entity but remains clinically controversial; evidence does not support prolonged antibiotic courses.

Medical Causes — Rheumatologic and Other

Systemic lupus erythematosus (SLE): fatigue is present in >90% of systemic lupus erythematosus patients and is often the most debilitating symptom — more disabling than arthritis or rash in many patients' self-reported experience. Systemic lupus erythematosus fatigue is multifactorial: disease activity, anemia, depression, fibromyalgia overlap, sleep disruption, and medication effects all contribute. Screening: antinuclear antibody (sensitivity >95% for systemic lupus erythematosus, but low specificity); if antinuclear antibody positive or clinical suspicion high, add anti-dsDNA, anti-Sm, complement C3/C4, complete blood count, urinalysis with microscopy.

Rheumatoid arthritis (RA): fatigue is a dominant complaint even when joint disease is well-controlled, affecting 70–80% of rheumatoid arthritis patients. Mechanisms include systemic inflammation (elevated tumor necrosis factor-alpha, interleukin-6, IL-6), anemia of chronic disease, pain-disrupted sleep, and depression. Initial workup: RF, anti-CCP antibodies (more specific than RF), ESR, C-reactive protein (CRP), complete blood count. Symmetric small joint involvement with morning stiffness exceeding one hour is the classic presentation.

Fibromyalgia: diffuse musculoskeletal pain + fatigue + unrefreshing sleep + cognitive symptoms ("fibro fog" — slowed processing, working memory difficulties) + multiple somatic complaints without objective inflammation. No diagnostic lab abnormality — diagnosis is clinical. The 2016 ACR criteria require widespread pain (>3 months, multiple body regions) plus symptom severity scale. Fibromyalgia overlaps significantly with myalgic encephalomyelitis/chronic fatigue syndrome, depression, and irritable bowel syndrome; presence of one does not exclude the others.

Chronic kidney disease (CKD): uremic fatigue (from nitrogenous waste accumulation) + fatigue from reduced erythropoietin production → normocytic anemia. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m² is associated with significant fatigue burden. Anemia of chronic kidney disease responds to ESA therapy (epoetin alfa, darbepoetin alfa) when Hgb <10 g/dL, per KDIGO guidelines, which target Hgb 10–11.5 g/dL to avoid cardiovascular risk from over-correction.

Celiac disease: fatigue + gastrointestinal symptoms (diarrhea, bloating, abdominal pain) + iron deficiency anemia unresponsive to oral iron replacement raises suspicion. Malabsorption of iron, B12, folate, and vitamin D all contribute to fatigue. Diagnosis: anti-tissue transglutaminase immunoglobulin A (TTG-IgA) + total immunoglobulin A (IgA) (to exclude immunoglobulin A deficiency as a false-negative cause); confirmed by small bowel biopsy (Marsh III lesions). A gluten-free diet results in dramatic energy improvement in confirmed celiac disease.

Medication-induced fatigue is extremely common and underappreciated. Major culprits: beta-blockers (reduce cardiac output response to exercise); first-generation antihistamines (diphenhydramine, hydroxyzine — cross the blood-brain barrier); benzodiazepines (especially long-acting — diazepam); opioids; statins (can cause myopathy with elevated creatine kinase (CK), which is checked when a patient reports muscle-related fatigue); antiepileptics (carbamazepine, valproate, topiramate); antipsychotics; interferon-based therapies; chemotherapy and hormonal cancer therapies (aromatase inhibitors, androgen deprivation). A systematic review of every medicine (medication reconciliation) is a standard part of a fatigue workup.

Depression and anxiety: fatigue is a DSM-5 criterion for major depressive disorder and is present in nearly all depressed patients. It is both a symptom of the mood disorder and a consequence of the sleep disruption, autonomic arousal, and hypothalamic-pituitary-adrenal dysregulation that depression produces. PHQ-9 score ≥10 has 88% sensitivity for major depression in primary care. Anxiety disorders produce fatigue through chronic sympathetic activation, hyperarousal-driven poor sleep, and energy depletion from constant worry. Treating the mood disorder often resolves the fatigue — but fatigue can also persist as a residual symptom requiring additional intervention.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS)

Myalgic encephalomyelitis/chronic fatigue syndrome is a serious, complex, multi-system illness characterized by profound fatigue that does not improve with rest and that is worsened by exertion. Its pathophysiology is incompletely understood but increasingly recognized as involving genuine biological dysfunction — not a functional or psychosomatic disorder. Prevalence: 0.8–2.5% of the general population; three times more common in females; peak onset in the 20s–40s, though all ages are affected. The illness frequently begins after an infectious trigger.

Post-infectious onset: myalgic encephalomyelitis/chronic fatigue syndrome often follows a viral illness — historically, Epstein-Barr virus, enteroviruses, and HTLV were most commonly implicated. Long COVID (post-COVID syndrome) has dramatically expanded the myalgic encephalomyelitis/chronic fatigue syndrome patient population: 10–20% of COVID-19 survivors develop long COVID, and a substantial subset meet formal myalgic encephalomyelitis/chronic fatigue syndrome criteria — making COVID-19 the most impactful myalgic encephalomyelitis/chronic fatigue syndrome trigger in history. Other infections (Q fever, Giardia, Ross River virus) have also been documented as triggers in epidemiological studies.

2015 IOM / SEID diagnostic criteria (all four required):

  1. Substantial reduction or impairment in the ability to engage in pre-illness levels of occupational, educational, social, or personal activities, lasting more than 6 months, accompanied by fatigue that is not the result of ongoing excessive exertion and is not substantially alleviated by rest
  2. Post-exertional malaise (PEM) — the cardinal hallmark: a worsening of ALL symptoms after minimal physical or cognitive exertion, often delayed 12–48 hours, that can last days to weeks and is severe enough to be temporarily debilitating. PEM distinguishes myalgic encephalomyelitis/chronic fatigue syndrome from depression, deconditioning, and most other fatigue states; patients often describe it as a "crash" or "relapse"
  3. Unrefreshing sleep — patients wake feeling as exhausted as before sleep; sleep study findings may show reduced deep sleep and increased light sleep stages, or alpha-wave intrusion
  4. Cognitive impairment ("brain fog") — reduced information processing speed, working memory deficits, word-finding difficulties, difficulty concentrating — OR orthostatic intolerance — worsening of symptoms upon standing, lightheadedness, palpitations, near-syncope, consistent with dysautonomia or postural orthostatic tachycardia syndrome-like physiology; tested with the NASA lean test or formal tilt-table test

Proposed pathophysiology: research increasingly points toward mitochondrial dysfunction (impaired oxidative phosphorylation + reduced adenosine triphosphate (ATP) production, documented by 2-day CPET showing abnormal VO2 and anaerobic threshold on day 2 despite normal day 1 — the "2-day CPET" signature); immune dysregulation (natural killer (NK) cell functional deficiency, cytokine network abnormalities, possible autoantibodies against adrenergic and muscarinic receptors); autonomic nervous system dysfunction (reduced baroreflex sensitivity, postural orthostatic tachycardia syndrome-like features in up to 30%); hypothalamic-pituitary-adrenal axis abnormalities (blunted cortisol response); and gut microbiome disruption (reduced microbial diversity, increased intestinal permeability).

Treatment — no curative therapy exists; management is supportive and symptom-targeted:

Diagnostic Workup

Initial Panel (commonly ordered when fatigue lasts more than 2 weeks)

Second-Tier Testing (targeted by clinical suspicion)

Psychological Screening

Treatment by Cause

Connections

Key Research Papers

Historical Background

The systematic medical study of fatigue as a distinct clinical entity began in earnest with George Beard's 1869 description of "neurasthenia" — a condition of nervous exhaustion attributed to the demands of modern industrial life. Beard's framework dominated for decades despite lacking mechanistic underpinning. The modern concept of post-viral fatigue crystallized through two pivotal American outbreaks in the mid-1980s: the 1984–1985 Lake Tahoe, Nevada outbreak (initially called "Raggedy Ann syndrome" and erroneously attributed to Epstein-Barr virus) and a concurrent Lyndonville, New York outbreak. These outbreaks, combined with a surge in clinical case series, prompted the U.S. Centers for Disease Control and Prevention to convene an expert panel that published the first formal case definition for chronic fatigue syndrome in 1988 (Holmes criteria), subsequently refined in the widely adopted 1994 Fukuda criteria.

The 2015 Institute of Medicine (IOM) report marked the most significant paradigm shift: renaming the condition Systemic Exertion Intolerance Disease (SEID), explicitly recognizing it as a biological illness distinct from psychiatric disorders, and elevating post-exertional malaise as the cardinal diagnostic criterion — a move that simultaneously improved diagnostic specificity and challenged the cognitive behavioral / graded exercise therapy models that had dominated treatment guidelines. The COVID-19 pandemic dramatically accelerated myalgic encephalomyelitis/chronic fatigue syndrome research: with 10–20% of COVID-19 survivors developing long COVID and a significant subset meeting myalgic encephalomyelitis/chronic fatigue syndrome criteria, the patient population expanded by millions globally, attracting NIH RECOVER Initiative funding and renewed scientific urgency. The parallel recognition that identical post-infectious mechanisms may drive both post-COVID and classical myalgic encephalomyelitis/chronic fatigue syndrome has generated the most promising mechanistic research in the field's history.

Key Research Papers

  1. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121(12):953-959. — doi:10.7326/0003-4819-121-12-199412150-00009
  2. Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press. 2015. — doi:10.17226/19012
  3. Dantzer R, Heijnen CJ, Kavelaars A, Laye S, Capuron L. The neuroimmune basis of fatigue. Trends Neurosci. 2014;37(1):39-46. — doi:10.1016/j.tins.2013.10.003
  4. Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry. 2003;160(2):221-236. — doi:10.1176/appi.ajp.160.2.221
  5. Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev. 2019;(10):CD003200. — doi:10.1002/14651858.CD003200.pub8
  6. NICE guideline NG206: Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management. National Institute for Health and Care Excellence. 2021.
  7. Rosenthal TC, Majeroni BA, Pretorius R, Malik K. Fatigue: an overview. Am Fam Physician. 2008;78(10):1173-1179. — PubMed PMID: 19035066
  8. Mullington JM, Haack M, Toth M, Serrador JM, Meier-Ewert HK. Cardiovascular, inflammatory, and metabolic consequences of sleep deprivation. Prog Cardiovasc Dis. 2009;51(4):294-302. — doi:10.1016/j.pcad.2008.10.003
  9. Wessely S, Chalder T, Hirsch S, Wallace P, Wright D. Psychological symptoms, somatic symptoms, and psychiatric disorder in chronic fatigue and chronic fatigue syndrome. Am J Psychiatry. 1996;153(8):1050-1059. — doi:10.1176/ajp.153.8.1050
  10. Natelson BH, Haghighi MH, Ponzio NM. Evidence for the presence of immune dysfunction in chronic fatigue syndrome. Clin Diagn Lab Immunol. 2002;9(4):747-752. — doi:10.1128/CDLI.9.4.747-752.2002
  11. Klimas NG, Koneru AO. Chronic fatigue syndrome: inflammation, immune function, and neuroendocrine interactions. Curr Rheumatol Rep. 2007;9(6):482-487. — doi:10.1007/s11926-007-0078-y
  12. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. — doi:10.1038/s41579-022-00846-2
  13. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17. — PubMed PMID: 16988643
  14. Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020. MMWR Recomm Rep. 2020;69(2):1-17. — PubMed PMID: 32271723
  15. Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome (with 2024 editorial note). Cochrane Database Syst Rev. 2024;12(12):CD003200. — PubMed PMID: 39697147
  16. Strayer DR, Carter WA, Stouch BC, et al. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One. 2012;7(3):e31334. — PubMed PMID: 22431963
  17. Stott DJ, Rodondi N, Kearney PM, et al. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. N Engl J Med. 2017;376(26):2534-2544. — PubMed PMID: 28402245
  18. Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017;4(11):e524-e533. — PubMed PMID: 29032957

PubMed Topic Searches

  1. PubMed: ME/CFS diagnosis and criteria
  2. PubMed: Fatigue evaluation in primary care
  3. PubMed: Post-exertional malaise in ME/CFS
  4. PubMed: Hypothyroidism and fatigue
  5. PubMed: Sleep apnea and fatigue
  6. PubMed: Long COVID and fatigue

Back to Table of Contents

Fatigue — scientific infographic poster